Scientists create single treatment that could provide life-long cure for a host of diseases


  • Bone marrow transplants are already used to treat leukaemia
  • Chemotherapy is used to kill current marrow – but side effects can kill  
  • Scientists have found a way to make body kill bone marrow cells itself
  • This means the life-saving infusions can be given risk-free
  • Will affect a myriad of diseases including type 1 diabetes, MS, cancer and organ transplantation

Fiona Macrae, Science Editor For The Daily Mail

38

View
comments

The treatment of diseases from diabetes to multiple sclerosis could be revolutionised by a breakthrough in bone marrow transplants.

Researchers have made the life-saving infusions so safe that they say they could be used to treat numerous conditions.

Excitingly, a single treatment could provide a life-long cure.

The scientists said their technique could be the ‘holy grail’ of transplantation, ushering in ‘a whole new era in disease treatment’.

Scientists have made life-saving bone marrow infusions so safe they could be used to re-set people’s immune systems, treating numerous conditions. Pictured, an immune cell

Some 1,200 bone marrow transplants are carried out each year in the UK.

Patients critically ill with leukaemia and other blood cancers are given radiotherapy or chemotherapy to wipe out their own diseased cells, before being given an infusion of healthy marrow.

But while they can be hugely successful, the transplants come with a host of side-effects and up to 20 per cent of patients die from complications.

As a result, bone marrow transplants are reserved for the most seriously ill.

Many of the problems are caused by the chemotherapy or radiotherapy that is used to wipe out the patient’s own bone marrow ahead of the transplant.

The Stanford University researchers have found a much safer way of eliminating the cells.

ARE WE ANOTHER STEP CLOSER TO PREVENTING ALZHEIMER’S? 

A cluster of genes in healthy brains could help researchers develop preventative treatments for Alzheimer’s disease. 

People with the gene ‘signature’ – a sequence of between 50 and 60 specific genes – are vulnerable to the spread of the killer illness which causes dementia.

They are vulnerable because they are less able to produce proteins that dispose of the rogue proteins that cause the plaques that clump around healthy brain cells and the tangles inside brain cells, leading to dementia.

University of Cambridge academics say the findings could be used to develop treatments for individuals well before symptoms appear.

At present, a genetic cause for Alzheimer’s has been found for only around 1 in 20 cases, and the researchers hope the breakthrough will cast light on the other 19 out of 20 cases that cannot be predicted.

They’ve used two different antibodies to trick the body into attacking the diseased marrow and destroying it.

In experiments in mice, more than 99 per cent of the bone marrow cells were eliminated, the journal Science Translational Medicine reports.

The team then found a way of purifying the donated bone marrow, to make the transplant even safer.

They said: ‘If it works in humans like it did in mice, we would expect the risk of death would drop form 20 per cent to effectively zero.’

Study co-author Irving Weissmann said: ‘There is almost no category of disease or organ transplant that is not impacted by this research.

‘If and when this is accomplished, it will be a whole new era in disease treatment and regenerative medicine.’

The bone marrow is the body’s blood cell ‘factory’ so transplants are usually used to treat blood cancers.

However, the marrow also makes most of the cells in the body’s immune system.

This means that any disease caused by a rogue immune response could potentially be cured by a one-off transplant.

Childhood diabetes, multiple sclerosis and rheumatoid arthritis and other autoimmune diseases could be the treatment’s grasp.

The technology could also be exploited to make heart, lung and other organ transplants safer.

The safe treatment could help a myriad of diseases including type 1 diabetes, MS, cancer and organ transplantation (file photo)

Co-researcher Judith Shizuru, a lab technician turned doctor, said human trials could start in as little as three years.

Dr Shizuru recently described the work as ‘they most exciting thing I have done in my whole life.’

She added: ‘One important reason why I became a bone marrow transplanter was so that I could help cure autoimmune disease.

‘If we can make bone marrow transplants safer, that offers a potential way to cure autoimmune disease, including diabetes.’

The Anthony Nolan blood cancer charity said the work was still in its early stages but showed promise.

Scientist Dr Aurore Saudemont, said: ‘Not only does it demonstrate better survival rates after a transplant but to herald a time where debilitating post-transplant side effects are reduced.

‘Such direct benefits to patients, for whom a transplant is often their last chance of life, could have a significant impact in this field. We look forward to seeing further results.’ 

Most watched News videos



  • Clever parrot masters perfect meow as he plays with three cats



  • Safety concerns delayed opening of waterslide that killed a boy



  • Thrilling moment woman swims near lava during volcanic eruption



  • EXCLUSIVE Incest mom: I’d give up my other kids for my lover



  • Lion tries to EAT screaming toddler on Mexican TV show



  • CCTV captures final tragic moments of Mirna Salihin’s life



  • Child killed in Kansas City water park accident



  • GoPro footage shows waterslide Verrückt that killed Missouri boy



  • EXCLUSIVE Incest son: I can’t plan who I fall in love with



  • If looks could kill: Phelps shoots death stare to Chad le Clos



  • Phelps basks in glory after winning 20th Olympic gold medal



  • Wife kicks out naked husband’s mistress from their flat


Comments (38)

Share what you think

The comments below have not been moderated.

The views expressed in the contents above are those of our users and do not necessarily reflect the views of MailOnline.

Find out now